Author: Newsdesk

ROSELAND, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, announced that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th – February 19th, 2021.

Leonard Osser, Interim Chief Executive Officer and Jan Adriaan Haverhals, President of Milestone Scientific, are scheduled to present on Tuesday, February 16th, 2021 at 3:00 PM, Eastern Time. The presentation will be webcast live and available for replay here. One-on-one meetings will be held throughout the conference via video conference calls.

About the Winter Wonderland Conference

The MicroCap Rodeo is hosting its “Winter Wonderland Conference- Best Ideas Bowl,” with 25-minute virtual presentations from the 16th to 17th, and one-on-ones for qualified institutional investors on the 18th and 19^th. This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. For more information, please visit the event website: https://microcaprodeo.com/.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology^® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR) (the “Company” or “Ideal Power”) , pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced the closing of an underwritten public offering of 1,352,975 shares of its common stock, which included 176,475 shares that were issued pursuant to the full exercise of the underwriter’s option to purchase additional shares, at a public offering price of $17.00 per share, before underwriting discounts and commissions, for an aggregate offering of approximately $23 million. The proceeds to the Company from this offering are expected to be approximately $21.1 million after deducting underwriting discounts and commissions and other estimated offering expenses.

The Benchmark Company, LLC acted as sole book-running manager for the offering. The Company intends to use the net proceeds from the offering to fund commercialization and development of its B-TRAN™ semiconductor technology and general corporate and working capital purposes.

The securities described above were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-250844) that was declared effective by the Securities and Exchange Commission (the “SEC”) on December 2, 2020.

A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on February 10, 2021 and is available for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ideal Power Inc.

Ideal Power (NASDAQ: IPWR) is pioneering the development of its broadly patented bi-directional power switches, creating highly efficient and ecofriendly energy control solutions for electric vehicle, electric vehicle charging, renewable energy, energy storage, UPS / data center and other industrial and military applications. The Company is focused on its patented Bi-directional, Bi-polar Junction Transistor (B-TRAN™) semiconductor technology. B-TRAN™ is a unique double-sided bi-directional AC switch able to deliver substantial performance improvements over today’s conventional power semiconductors. Ideal Power believes B-TRAN™ modules will reduce conduction and switching losses, complexity of thermal management and operating cost in medium voltage AC power switching and control circuitry. For more information, visit www.IdealPower.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Ideal Power’s intended use of proceeds from the offering. While Ideal Power’s management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of Ideal Power’s control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties associated with market conditions, as well as risks and uncertainties set forth in Ideal Power’s quarterly, annual and other reports filed with the SEC. Furthermore, Ideal Power operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Ideal Power disclaims any intention to, and undertake no obligation to, update or revise forward-looking statements.

Ideal Power Investor Relations Contact: 

LHA Investor Relations
Carolyn Capaccio, CFA; Keith Fetter
T: 212-838-3777
[email protected]

Source: Ideal Power Inc.

NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) — Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare.

“We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more convenient and on demand access to healthcare, prescriptions and over-the-counter medications.”
        
Life MD will offer virtual on-demand access to highly qualified licensed physicians across all 50 states. Its mobile-first interface will be powered by the company’s proprietary Veritas MD digital health platform, providing a seamless integration between doctors, patients, medical information, and pharmacy. Patients will be intelligently and dynamically paired with the right physician based on the patients’ needs, goals and lifestyle.

“Our vision is to dramatically improve the healthcare experience of our patients with highly personalized care, akin to having a doctor in the family,” added Schreiber. “Life MD represents an important and valuable opportunity to support the long-term health of our patients by fostering longitudinal relationships that create better health and well-being.”

To support the nationwide rollout of Life MD and further expand the company’s telehealth pipeline, Conversion Labs has completed a $14 million unregistered private placement at $23 per share with certain individual and institutional investors. BTIG, LLC acted as exclusive placement agent for the offering.

Stefan Galluppi, company co-founder and chief technology officer, commented: “As one of the earliest and largest players in the telemedicine space, we have been able to capitalize on the major paradigm shift in healthcare created by advancements in digital health technology and increasing widespread customer demand for virtual healthcare services.”

“This investment by a select group of strategic investors, including those from prior financing rounds, affirms the strength of our business strategy and growth outlook as a national leader in telehealth,” continued Galluppi. “The additional capital will support our aggressive growth initiatives, including scaling the size and reach of our digital health ecosystem, expanding our suite of brands for men’s and women’s health, and accelerating customer acquisition and adoption of our existing brands and new concierge services.”

The company recently relaunched its popular Shapiro MD hair products for men and women under a new subscription-based model, similar to Rex MD’s subscription-based model introduced early last year. The company is also preparing to launch Nava MD, the company’s teledermatology brand for women supported by a patented and clinically proven OTC technology platform.

The company recently reported preliminary results for 2020, with revenue up 205% to $38.0 million. The record month of December ended the year at a $60 million annualized revenue run-rate. Annual recurring revenue (ARR) generated by subscriptions is expected to total $26.0 million at yearend 2020, up 525% versus yearend 2019.

Upon the name change on February 22, the company expects its common stock to begin trading under the symbol, LFMD.

About the Private Placement

The securities sold by Conversion Labs in the private placement were not registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements and exemptions under applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Additional details of the private placement can be found in the company’s current report on Form 8-K filed with the U.S. Securities and Exchange Commission and available at sec.gov, and from the Investors section of the company’s website at ir.conversionlabs.com.

About Conversion Labs

Conversion Labs, Inc. is a leading telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.

Annual Recurring Revenue

Conversion Labs calculates its annual recurring revenue (ARR) by multiplying by 12 the monthly sum of revenue attributed exclusively to automatic subscription sales from customers that are engaged in the company’s rebill structure as it applies to its main brands: Shapiro MD, Rex MD and PDFSimpli. In the company’s calculation of ARR, it does not consider single sales from customers that repurchase its products through the company’s standard checkout pages, Amazon Marketplace or involving the assistance of a customer service representatives. It also does not include revenue from the initial purchase of a new subscriber.

Important Cautions Regarding Forward-Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects — both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

Life MD™, Veritas MD™, Shapiro MD™, Rex MD™ and Nava MD™ are trademarks of Conversion Labs. All other trademarks are the property of their respective owners.

Company Contact                                
Conversion Labs        
Email Contact        

Media and Investor Relations Contact

Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact

DENVER, Feb. 12, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences:

• MicroCap Rodeo Winter Wonderland Conference February 16-19, 2021. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas. Assure’s executive chairman and CEO John Farlinger is scheduled to present on February 17th at 1:00 p.m. ET with one-on-one meetings held throughout the conference. Register for the webcast here: https://www.webcaster4.com/Webcast/Page/2134/39974
• 33^rd Annual ROTH Conference March 15-17, 2021. This gathering is expected to include thousands of institutional, private equity, venture capital, family office and high net-worth investors engaged in the small and mid-cap space. Assure management will be meeting with investors at the conference.
• Planet MicroCap Showcase Investor Conference April 20-22, 2021. This event brings together promising companies with influential microcap investors, fund managers and newsletter writers for company presentations and one-on-one meetings. Assure’s executive chairman and CEO John Farlinger is scheduled to present on April 21st at 1:00 p.m. ET with one-on-one meetings held throughout the conference. Register for the webcast here: https://www.webcaster4.com/Webcast/Page/2059/40053

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to: the expected attendees of the conferences and the Company’s ability to meet with the attendees. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the expected attendees may not attend one or more of the conferences; the Company may not meet with the targeted investors at the conferences the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general, and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
[email protected]

John Farlinger, Chief Executive Officer
Assure Holdings Corp.
1-604-763-7565
[email protected]

GreenBox is working with Visa to deliver the next innovation in payments

SAN DIEGO, CA, Feb. 12, 2021 (GLOBE NEWSWIRE) — GreenBox POS (OTCQB: GRBX) (“GreenBox”, the “Company”), an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions today announced that it has joined Visa’s Fintech Fast Track program, speeding up the process of integrating with Visa. By joining Fast Track, GreenBox is able to more easily leverage the reach, capabilities, and security that VisaNet, the company’s global payment network, offers. Through Visa Fast Track and working with Visa Fast Track partners, GreenBox will be issuing a co-branded Visa card and enabling direct push-to-card payments.

GreenBox operates a private and proprietary blockchain payment platform that offers security and data privacy, as well as enhanced fraud protection and rapid speed to settlement. Serving as the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time.

Visa’s Fintech Fast Track Program provides companies like GreenBox the ability to access Visa’s growing partner network, and experts who can provide guidance in helping them get up and running in the most efficient way possible. Learn more about Visa’s Fintech Fast Track program at https://Partner.Visa.com.

“Our partnership with Visa marks another important step aligned with our goal to help move society towards cashless, secure payments where digital currency can be moved anywhere at any time,” said Fredi Nisan, Chief Executive Officer of GreenBox POS. “Being able to issue payment credentials and send near real-time payments across the Visa network significantly enhances our payment solutions offering.”

“By joining Visa’s Fast Track program, exciting Fintechs like GreenBox POS gain extraordinary access to Visa experts, technology, and resources,” said Terry Angelos, SVP and Global Head of Fintech, Visa. “Fast Track lets us provide new resources that rapidly growing companies need to scale with efficiency.”

About GreenBox POS

GreenBox POS (OTCQB: GRBX) is an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions. The Company’s applications enable an end-to-end suite of turnkey financial products, helping to reduce fraud and improve the efficiency of handling large-scale commercial processing volumes for its merchant clients globally. For more information, please visit the Company’s website at www.greenboxpos.com.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements.

Investor Relations Contact

Mark Schwalenberg
MZ Group – MZ North America
312-261-6430
[email protected]
www.mzgroup.us